학술논문
Concordance of PD-L1 expression and [CD8.sup.+] TIL intensity between NSCLC and synchronous brain metastases
RESEARCH ARTICLE: PATHOLOGY
non-small-cell lung carcinoma
RESEARCH ARTICLE: PATHOLOGY
non-small-cell lung carcinoma
Document Type
Report
Author
Source
Bosnian Journal of Basic Medical Sciences. August 2020, Vol. 20 Issue 3, p329, 7 p.
Subject
Language
English
ISSN
1512-8601
Abstract
INTRODUCTION Immunotherapies targeting the programmed cell death protein 1 (PD-1) and/or programmed death-ligand 1 (PD-L1) are relatively new and promising cancer therapeutic options. Since the discovery of PD-1/PD-L1 pathway and [...]
Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes (TILs) and [CD8.sup.+] TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values KEYWORDS: Programmed death-ligand 1; non-small-cell lung cancer; NSCLC; tumor immunology; PD-L1; brain metastasis; CD8 lymphocytes; tumor-infiltrating lymphocytes; TILs
Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes (TILs) and [CD8.sup.+] TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values KEYWORDS: Programmed death-ligand 1; non-small-cell lung cancer; NSCLC; tumor immunology; PD-L1; brain metastasis; CD8 lymphocytes; tumor-infiltrating lymphocytes; TILs